5VT0.F vTv Therapeutics Inc.
- Market cap
- EUR 74.2M
- P/E
- -
- P/B
- 1.17x
- ROE
- -1.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 5VT0.F undervalued?
Graham numberThe Graham number of vTv Therapeutics Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
vTv Therapeutics Inc. fundamental analysis
No fundamental analysis for vTv Therapeutics Inc. yet.
vTv Therapeutics Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About vTv Therapeutics Inc.
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic d…
Full company profilevTv Therapeutics Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
vTv Therapeutics Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 4.01M | 2.02M | 0.00 | 1.02M | 0.00 | 49.1M |
| Operating Income | -21.7M | -22.5M | -25.5M | -24.2M | -32.8M | -4.12M |
| EBITDA | - | -24.8M | -25.9M | -22.5M | -31.1M | -3.05M |
| Net Income | -13.0M | -19.2M | -20.3M | -18.5M | -27.0M | -720K |
| EPS | -7.76 | -9.41 | -9.71 | -7.07 | -6.85 | -0.18 |
| Balance Sheet | ||||||
| Total Assets | 25.5M | 33.2M | 11.0M | 38.3M | 89.9M | 78.6M |
| Total Liabilities | 10.3M | 27.4M | 29.6M | 24.0M | 25.5M | 8.92M |
| Shareholders' Equity | -9.74M | -10.7M | -24.7M | 12.2M | 64.4M | 69.7M |
| Cash & Short-term Investments | 13.4M | 12.1M | 9.45M | 36.7M | 88.9M | 77.2M |
| Cash Flow | ||||||
| Operating Cash Flow | -19.3M | -16.0M | -19.1M | -25.3M | -25.3M | -16.6M |
| Capital Expenditure | 0.00 | 21.0K | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -19.3M | -16.0M | -19.1M | -25.3M | -25.3M | -16.6M |
| Ratios | ||||||
| ROE | - | - | - | -151.3% | -41.9% | -1.0% |
| ROA | -51.0% | -57.7% | -183.8% | -48.2% | -30.0% | -0.9% |
| Net Profit Margin | -324.3% | -949.7% | - | -1,815.3% | - | -1.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
vTv Therapeutics Inc. dividends
vTv Therapeutics Inc. has not paid dividends in the last 5 fiscal years.
Last stock split: 1:40 on Nov 21, 2023.
Who owns vTv Therapeutics Inc.
- Insiders 38.83%
- Institutions 42.64%
- Public & others 18.53%
- Shares outstanding 4.01M
- Free float 2.16M
vTv Therapeutics Inc. company profile
- Company name
- vTv Therapeutics Inc.
- Ticker
- 5VT0.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 26
- Fiscal year end
- December
- Address
- 3980 Premier Drive, High Point, NC, United States, 27265
- Phone
- 336 841 0300
- Website
- vtvtherapeutics.com
About vTv Therapeutics Inc.
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.
vTv Therapeutics Inc. management
8- Mr. Paul J. SekhriCEO, President & Chairman of the Board · born 1958
- Dr. Michael Steven Tung M.B.A., M.D.Executive VP & CFO · born 1974
- Mr. Barry K. BrownChief Accounting Officer · born 1961
- Dr. Carmen Valcarce Ph.D.Chief Scientific Officer & Executive VP
- Ms. Elizabeth M. KeileyExecutive VP & General Counsel · born 1966
- Mr. Richard S. NelsonExecutive VP of Corporate Development & Director · born 1970
- Dr. Thomas Strack M.D., Ph.D.Chief Medical Officer
- Mr. Martin LafontaineChief Commercial Officer